Skip to main content
. 2019 Sep 13;11(9):1361. doi: 10.3390/cancers11091361

Figure 3.

Figure 3

Intra-tumour heterogeneity (ITH) temporal analysis and PanDrugs prescription. TimeScape representation shows the clonal evolution for acute myeloid leukaemia (AML) patient UPN933124. Clonal prevalence (vertical axis) are plotted across timepoints for each clone (C1–C5). The evolutionary relationships between clones are captured by the phylogenetic tree. Variant allele frequency (VAF) is reported in parentheses and those genes that were clone-specific are written in white. Three genes (ERBB4, FLT4 and ETV6), highlighted in bold, had a sensitivity response to Food and Drug Administration (FDA) approved drugs with a Drug Score > 0.7, which are detailed in the table below. Those drugs directed against several targets are written in bold and those approved for blood cancer are underlined. The type of target for each drug is reported (tg: direct target; bm; biomarker; pa: pathway member).